Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
03 10월 2023 - 10:00PM
Business Wire
- The scientific poster highlights the role of pro-inflammatory
macrophages and monocytes in reducing regulatory T cell (Treg)
immunomodulatory suppressive function and the anti-inflammatory
effect of Treg-enhancing therapies combined with drugs that
suppress M1 pro-inflammatory activated monocytes and macrophages in
ALS;
- COYA 302 is a dual-mechanism investigational biologic
combination comprised of proprietary low dose interleukin-2 (LD
IL-2) and CTLA-4 Ig and is being investigated for the treatment of
ALS.
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the
“Company”), a clinical-stage biotechnology company developing
biologics and cell therapies intended to enhance the function of
Tregs, today announced the acceptance and presentation of a poster
at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting on
October 4th, 2023.
The experimental data generated in samples from ALS patients
highlight the role of M1 pro-inflammatory monocytes and macrophages
in reducing the immunomodulatory anti-inflammatory function of
Tregs. Also documented is the significant effect of combination
therapies that both enhance Treg function and suppress M1 activated
macrophages and monocytes resulting in the reduction of
pro-inflammatory cytokines known to be involved in inflammatory
response and tissue damage. Results of this study reinforce the
potential of COYA 302 that may address the complex pathophysiology
and multiple pathways involved in the progression and severity of
ALS.
Fred Grossman, President and Chief Medical Officer said, “The
data being presented provides additional mechanistic rationale and
support for combination therapies targeting multiple immune
pathways in ALS.”
Details of the poster presentation at the NEALS Annual Meeting
are as follows:
Date: October 5th, 2023 Title: Monocytes/Macrophages Impair
Regulatory T-Lymphocyte Suppressive Function Poster Number: 132
For Conference Information visit:
https://neals.org/als-researchers/annual-neals-meeting
About Coya Therapeutics, Inc.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq:
COYA) is a clinical-stage biotechnology company developing
proprietary treatments focused on the biology and potential
therapeutic advantages of regulatory T cells (“Tregs”) to target
systemic inflammation and neuroinflammation. Dysfunctional Tregs
underlie numerous conditions including neurodegenerative,
metabolic, and autoimmune diseases, and this cellular dysfunction
may lead to a sustained inflammation and oxidative stress resulting
in lack of homeostasis of the immune system. Coya’s investigational
product candidate pipeline leverages multiple therapeutic
modalities aimed at restoring the anti-inflammatory and
immunomodulatory functions of Tregs. Coya’s lead therapeutic
programs includes Treg-enhancing biologics (COYA 300 Series product
candidates) COYA 301 and COYA 302, which are intended to enhance
Treg function and expand Treg numbers. COYA 301 is a proprietary
investigational recombinant human low dose IL-2 biologic for
subcutaneous administration intended to enhance Treg function and
expand Treg numbers in vivo, and COYA 302 is a dual-mechanism
investigational biologic combination comprised of proprietary low
dose IL-2 and CTLA-4 Ig. The low dose IL-2 is intended to enhance
anti-inflammatory regulatory T cell function and numbers while the
fusion protein CTLA-4 Ig is intended to suppress pro-inflammatory
cell function. These two mechanisms may be additive or synergistic
in suppressing inflammation. For more information about Coya,
please visit www.coyatherapeutics.com
Forward-Looking Statements
This press release contains “forward-looking” statements that
are based on our management’s beliefs and assumptions and on
information currently available to management. Forward-looking
statements include all statements other than statements of
historical fact contained in this presentation, including
information concerning our current and future financial
performance, business plans and objectives, current and future
clinical and preclinical development activities, timing and success
of our ongoing and planned clinical trials and related data, the
timing of announcements, updates and results of our clinical trials
and related data, our ability to obtain and maintain regulatory
approval, the potential therapeutic benefits and economic value of
our product candidates, competitive position, industry environment
and potential market opportunities. The words “believe,” “may,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,”
and similar expressions are intended to identify forward-looking
statements.
Forward-looking statements are subject to known and unknown
risks, uncertainties, assumptions and other factors including, but
not limited to, those related to risks associated with the impact
of COVID-19; the success, cost and timing of our product candidate
development activities and ongoing and planned clinical trials; our
plans to develop and commercialize targeted therapeutics; the
progress of patient enrollment and dosing in our preclinical or
clinical trials; the ability of our product candidates to achieve
applicable endpoints in the clinical trials; the safety profile of
our product candidates; the potential for data from our clinical
trials to support a marketing application, as well as the timing of
these events; our ability to obtain funding for our operations;
development and commercialization of our product candidates; the
timing of and our ability to obtain and maintain regulatory
approvals; the rate and degree of market acceptance and clinical
utility of our product candidates; the size and growth potential of
the markets for our product candidates, and our ability to serve
those markets; our commercialization, marketing and manufacturing
capabilities and strategy; future agreements with third parties in
connection with the commercialization of our product candidates;
our expectations regarding our ability to obtain and maintain
intellectual property protection; our dependence on third party
manufacturers; the success of competing therapies or products that
are or may become available; our ability to attract and retain key
scientific or management personnel; our ability to identify
additional product candidates with significant commercial potential
consistent with our commercial objectives; and our estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing.
We have based these forward-looking statements largely on our
current expectations and projections about future events and trends
that we believe may affect our financial condition, results of
operations, business strategy, short-term and long-term business
operations and objectives, and financial needs. Moreover, we
operate in a very competitive and rapidly changing environment, and
new risks may emerge from time to time. It is not possible for our
management to predict all risks, nor can we assess the impact of
all factors on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements
we may make. In light of these risks, uncertainties and
assumptions, the forward-looking events and circumstances discussed
herein may not occur and actual results could differ materially and
adversely from those anticipated or implied in the forward-looking
statements. Although our management believes that the expectations
reflected in our forward-looking statements are reasonable, we
cannot guarantee that the future results, levels of activity,
performance or events and circumstances described in the
forward-looking statements will be achieved or occur. We undertake
no obligation to publicly update any forward-looking statements,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003120517/en/
Investor Contact David Snyder
david@coyatherapeutics.com
Hayden IR James Carbonara 646-755-7412
James@haydenir.com
Media Contact Anna Marie Imbordino
annamarie@quantum-corp.com 917-680-8765
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Coya Therapeutics (NASDAQ:COYA)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024